<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147637</url>
  </required_header>
  <id_info>
    <org_study_id>RA HM-2019-027</org_study_id>
    <nct_id>NCT04147637</nct_id>
  </id_info>
  <brief_title>FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia</brief_title>
  <acronym>FSL-M</acronym>
  <official_title>Crossover Randomized Controlled Trial of FreeStyle Libre Plus Bluetooth Transmitter Compared to FreeStyle Libre Alone in People With Type 1 Diabetes Mellitus. Can This Improve Accuracy and Reduce Burden of Hypoglycaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dasman Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dasman Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced glucose monitoring systems have revolutionized diabetes care and enabled people with&#xD;
      diabetes to achieve better diabetes control with reduced risk of hypoglycaemia. Continuous&#xD;
      glucose monitoring (CGM) systems provide real-time glucose monitoring and alarms when glucose&#xD;
      approaches extreme readings (hypoglycaemia and hyperglycaemia) or when the change in glucose&#xD;
      is rapid. All available CGM systems, except Dexcom G6, require daily calibrations with&#xD;
      capillary glucose readings in order to attain accuracy of glucose readings. Decom G6 system&#xD;
      is not widely accessible and only available in certain countries. Flash glucose monitoring&#xD;
      systems (Flash) provide glucose readings when users actively scan their sensors. FreeStyle&#xD;
      Libre (FSL) is the only Flash glucose monitoring system currently available in market. FSL is&#xD;
      factory calibrated and sensors are ready to use after placement and initiation. The two main&#xD;
      differences between Flash and CGM are user interaction and the alarm facility. While CGM&#xD;
      provide real-time glucose readings, Flash is user-dependent for actively scanning and&#xD;
      understanding the readings. Moreover, CGM systems provide alarms for low or high glucose and&#xD;
      for rapid glucose changes, while Flash does not routinely provide alarms. This is&#xD;
      particularly relevant when patients have impaired or lost hypoglycaemia awareness. CGM&#xD;
      systems are costlier compared to Flash, which has contributed to the wider adoption of FSL.&#xD;
&#xD;
      Several Bluetooth adjuncts have been introduced to market for FSL. These devices attach to&#xD;
      Libre sensor and connect to the user's mobile phone via Bluetooth. This enables continuous&#xD;
      and real-time feed of glucose readings from the sensor to patient's mobile phone, which&#xD;
      enables a wide range of customizable alarms for high and low glucose levels and for rapid&#xD;
      glucose changes. This setup also enables calibration of Libre sensor with capillary glucose&#xD;
      which, anecdotally, has been reported to improve sensor accuracy. None of these adjuncts have&#xD;
      been validated clinically. FSL with Bluetooth adjunct such as MiaoMiao remain cheaper than&#xD;
      current CGM options and could be more accessible in some countries than CGM. However, without&#xD;
      robust evidence to support effectiveness and safety of such setup it is not possible to&#xD;
      recommend this.&#xD;
&#xD;
      The Objective of this study is to determine whether FSL with Bluetooth Adjunct is superior to&#xD;
      FSL alone in accuracy and reduction of hypoglycaemia burden.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      Open-label, crossover, single center, randomized controlled trial of FreeStyle Libre with&#xD;
      MiaoMiao Bluetooth transmitter adjunct with calibrations (FSL-M) compared to FreeStyle Libre&#xD;
      alone (FSL-A) in people with T1DM.&#xD;
&#xD;
      Protocol summary:&#xD;
&#xD;
      Following informed written consent, subjects will be randomized to either FSL-M group using&#xD;
      FSL with Miaomio and Tomato App premium version, or FSL-A with Libre Link app (stage 1).&#xD;
      Subjects will spend 8 weeks in the assigned group followed by 2 weeks washout then subjects&#xD;
      will switch over to the other group for further 8 weeks (stage 2).&#xD;
&#xD;
      While in FSL-M, subjects will be asked to calibrate FSL with daily capillary glucose values&#xD;
      using Contour Plus, or on days 1, 2, 4, 8, 13 of sensor life. Alarms for low glucose&#xD;
      (&lt;3.9mmol/L, &lt;70mg/dL) and high glucose (&gt;13.9mmol/L, 250mg/dL) will be set in Tomato App.&#xD;
&#xD;
      7-point capillary glucose profiles will be carried out by subjects in both groups on days&#xD;
      2/3, 5/6, 9/10, 13/14 of each sensor life to enable paired comparison with sensor values.&#xD;
&#xD;
      Subjects will have routine labs at randomization, end of stage 1, and end of stage 2. All&#xD;
      subjects will be asked to complete the following questionnaires: GOLD, Problem Areas in&#xD;
      Diabetes (PAID) and Diabetes Quality of Life (DQOL) at randomization, at end of stage1 and&#xD;
      end of stage 2. The group randomized to FSL-M at stage 1 will have qualitative interview at&#xD;
      randomization, end of stage 1 and end of stage 2.&#xD;
&#xD;
      All adverse events will be collected including, but not limited to, all hypoglycaemia,&#xD;
      diabetic ketoacidosis, hospital admissions for any reason, and device related skin reaction&#xD;
      for the duration of the study in all subjects in both groups.&#xD;
&#xD;
      Data analysis will be carried out on glucose data retrieved from Libre view web-platform and&#xD;
      Tomato App downloads in addition to Contour Plus meter downloads.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    due to irrelevancy of the idea given the advancement in the field and COVID-19 crisis&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 14, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized crossover study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean absolute relative difference (MARD)</measure>
    <time_frame>9 months</time_frame>
    <description>Comparing difference between glucose readings from the sensor in comparison to reference paired capillary glucose readings. This is to enable assessing accuracy of the intervention with FSL and MiaoMiao</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage time below 3.0mmol/L (54mg/dL)</measure>
    <time_frame>9 months</time_frame>
    <description>This is to enable evaluating burden of hypoglycaemia. Analysis will be done on sensor glucose data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage time in range 4-10mmol/L</measure>
    <time_frame>9 months</time_frame>
    <description>This is to enable effect on time spent in normoglycaemia. Analysis will be done on sensor glucose data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage time &lt;4mmol/L (72mg/dL)</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate general hypoglycaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage time &gt;10mmol/L</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate hyperglycaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate for any change in overall diabetes control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hypoglycaemia</measure>
    <time_frame>9 months</time_frame>
    <description>number of episodes of hypoglycaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe hypoglycaemia</measure>
    <time_frame>9 months</time_frame>
    <description>number of episodes of severe hypoglycamia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device-related complications</measure>
    <time_frame>9 months</time_frame>
    <description>This is specific for Libe and/or MiaoMiao</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dose of insulin</measure>
    <time_frame>9 months</time_frame>
    <description>This will compare before and at end of each phase total daily insulin dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>FSL-M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSL-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FreeStyle Libre alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>FreeStyle Libre with MiaoMiao</intervention_name>
    <description>Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms</description>
    <arm_group_label>FSL-M</arm_group_label>
    <other_name>FSL-M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeStyle Libre alone</intervention_name>
    <description>Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning</description>
    <arm_group_label>FSL-A</arm_group_label>
    <other_name>FSL-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. T1DM for 12 months or more&#xD;
&#xD;
          2. Age &gt;21 years old&#xD;
&#xD;
          3. Established user of FreeStyle Libre for â‰¥3 months&#xD;
&#xD;
          4. HbA1C &lt;12% (108mmol/mol)&#xD;
&#xD;
          5. Able to check glucose with finger prick several times a day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or plans for pregnancy over the duration of the study&#xD;
&#xD;
          2. Breast feeding&#xD;
&#xD;
          3. Renal impairment with eGFR &lt;30ml/minute/1.73m2&#xD;
&#xD;
          4. Significant anaemia (males Hb&lt;110g/L, females Hb &lt;100g/L)&#xD;
&#xD;
          5. Active malignancy&#xD;
&#xD;
          6. Significant vision impairment&#xD;
&#xD;
          7. Any significant illness- decision will be made by the PI or Co-I&#xD;
&#xD;
          8. Not able to attend study visits&#xD;
&#xD;
          9. Not able or not willing to participate in all study components&#xD;
&#xD;
         10. Not able or not willing to give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Aldibbiat, MD PhD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dasman Diabetes Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ali Aldibbiat</name>
      <address>
        <city>Kuwait City</city>
        <zip>15462</zip>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kuwait</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hytpoglycemia</keyword>
  <keyword>FreeStyle Libre</keyword>
  <keyword>Flash Glucose Monitoring</keyword>
  <keyword>MiaoMiao</keyword>
  <keyword>Time in Range</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

